Main roads
-
Professional scientists at the Food and Drug Administration recommend complex access to peptides against RFK Jr.’s pressure.
-
The advisory panel, which reviews the seven peptides, includes several members with ties to clinics and peptide companies.
-
Peptides like BPC-157 are being marketed for anti-aging and muscle building purposes despite limited safety and efficacy data.
WEDNESDAY, July 1, 2026 (NewsDay News) – Federal health scientists are wary of expanding access to controversial peptide drugs, even as the U.S. Food and Drug Administration (FDA) renews an advisory panel that is considering lifting those restrictions.
FDA professional scientists quietly published recommendations Monday in a series of briefing papers that advise against relaxing the rules that would allow pharmacies to produce seven peptides for use. ulcerative colitis to insomnia and obesityinforms Newspaper “Washington Post”..
State scientists have determined that there is insufficient evidence on the effectiveness and safety of peptides.
The recommendation puts agency experts at odds with the U.S. Secretary of Health and Human Services (HHS). Robert Kennedy Jr.described a “big fan” of his peptides, who said he used them on wounds with “really good results.”
Also Monday, the FDA released a list of participants for its two-day July meeting Joint Pharmacy Advisory Committee. At least seven members have ties to peptide companies or clinics, the report said Associated Press Agency.
Peptides, short chains of amino acids, are increasingly being marketed by wellness clinics and online retailers as a way to build muscle, heal injuries and slow aging. But many have not passed serious clinical trials.
The FDA has warned about the safety risks of injectables BPC-157 and TB-500, both of which are considered doping agents by international sports authorities.
According to earlier versions of the same FDA panel, it consisted mainly of experts from universities, including Duke, Harvard and Johns Hopkins. AP News. Those panels have repeatedly voted against allowing peptide ingredients into complex drugs, declaring them too dangerous for patients.
Instead, the new group includes doctors and pharmacists who run peptide clinics, sell peptide injections, or advertise drugs online. AP.
Also on the panel is a Tennessee state senator. Bobby Harshbargera pharmacist whose mother is a US representative. Diana Harshbargersent a letter to Kennedy last year urging him to ease restrictions on several peptides. Both Harshbargers are Republicans.
HHS spokesperson Emily Hilliard The committee members reportedly went through the same ethics review required of all FDA advisory candidates, and anyone who didn’t meet the requirements was removed from consideration. Newspaper “Washington Post”..
Outside experts are skeptical of the rebuild.
“Looks like RFK Jr. assembled the committee” Paul Knoepfflersaid a professor at the University of California, Davis, School of Medicine, who is pursuing unproven uses of peptides The Post. “This certainly seems like a group that could defy FDA staff.”
Dr. Peter Luriepresident of the Center for Science in the Public Interest and a former FDA official, said the “review” panel typically excludes members who have a financial interest in the vote.
The FDA is not required to follow the advice of its advisory committees, but often does.
The final determination of the seven peptides is expected after the July meeting.
More information
Visit the US Food and Drug Administration website for more information mixed drugs.
SOURCES: Associated Press AgencyJune 29, 2026; Newspaper “Washington Post”.June 30, 2026
What does this mean for you?
If you’re considering peptide injections marketed for anti-aging, muscle building or injury recovery, be aware that the US Food and Drug Administration has cited safety concerns and many have not been rigorously tested for effectiveness.
